Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
36.36
-0.26 (-0.71%)
At close: Sep 4, 2026, 4:00 PM EDT
37.19
+0.83 (2.28%)
After-hours: Sep 4, 2026, 7:59 PM EDT
Teva Pharmaceutical Industries Employees
Teva Pharmaceutical Industries had 33,950 employees as of December 31, 2025. The number of employees decreased by 2,880 or -7.82% compared to the previous year.
Employees
33,950
Change (1Y)
-2,880
Growth (1Y)
-7.82%
Revenue / Employee
$510,015
Profits / Employee
$20,795
Market Cap
42.37B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33,950 | -2,880 | -7.82% |
| Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
| Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
| Dec 31, 2022 | 36,826 | -711 | -1.89% |
| Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
| Dec 31, 2020 | 40,216 | 177 | 0.44% |
| Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
| Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
| Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
| Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
| Dec 31, 2015 | 42,888 | -121 | -0.28% |
| Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
| Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
| Dec 31, 2012 | 45,948 | 194 | 0.42% |
| Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
| Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
| Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
| Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
| Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
| Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
| Dec 31, 2005 | 14,698 | 885 | 6.41% |
| Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
| Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
| Dec 31, 2002 | 9,577 | 591 | 6.58% |
| Dec 31, 2001 | 8,986 | 361 | 4.19% |
| Dec 31, 2000 | 8,625 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
TEVA News
- 12 hours ago - S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline - GlobeNewsWire
- 18 hours ago - Teva price target raised to $48 from $42 at UBS - TheFly
- 1 day ago - Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains - Nasdaq
- 2 days ago - A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% Gain -- GF Value $20. ... - GuruFocus
- 2 days ago - Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study - MarketBeat
- 2 days ago - Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease - Nasdaq
- 2 days ago - TEVA Looks 74.7% Overvalued on GF Value⢠as Phase 2a Trial Data Emerges - GuruFocus
- 2 days ago - TEVA Looks 74.7% Overvalued on GF Value⢠as Positive Trial News Boosts Sentiment - GuruFocus